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Abstract: 11β-Hydroxysteroid dehydrogenase type1 (11βHSD1) regulates the conversion 
from  inactive  cortisone  to  active  cortisol.  Increased  cortisol  results  in  diabetes,  hence 
quelling the activity of 11βHSD1 has been thought of as an effective approach for the 
treatment of diabetes. Quantitative hypotheses were developed and validated to identify the 
critical  chemical  features  with  reliable  geometric  constraints  that  contribute  to  the 
inhibition of 11βHSD1 function. The best hypothesis, Hypo1, which contains one-HBA;  
one-Hy-Ali, and two-RA features, was validated using Fischer’s randomization method, a 
test and a decoy set. The well validated, Hypo1, was used as 3D query to perform a virtual 
screening  of  three  different  chemical  databases.  Compounds  selected  by  Hypo1  in  the 
virtual screening were filtered by applying Lipinski’s rule of five, ADMET, and molecular 
docking.  Finally,  five  hit  compounds  were  selected  as  virtual  novel  hit  molecules  for 
11βHSD1 based on their electronic properties calculated by Density functional theory. 
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1. Introduction 
Glucocorticoids are a class of steroid hormones which bind to the glucocorticoid receptor. The 
glucocorticoids name was derived from their role in the regulation of glucose metabolism and from 
their  synthesis.  Glucocorticoids  play  an  important  role  in  the  regulation  of  multiple  physiological 
processes such as energy metabolism, maintenance of blood pressure, stress responses, and cognitive 
functions. The dysregulation of glucocorticoids has been implicated in the pathogenesis of diabetes 
and metabolic syndromes. The major glucocorticoid, cortisol, is normal in healthy individuals but the 
increased level in the intracellular adipose tissue could be responsible for ―visceral obesity‖. Cortisol is 
an important regulator of fuel metabolism during the starvation and stress which is modulated by  
11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and 11β-hydroxysteroid dehydrogenase type 2 
(11βHSD2). 11βHSD1, a NADP(H)
+-dependent bidirectional enzyme, was highly expressed in the 
liver [1], adipose tissue [2] as well as found in a number of other tissues such as brain [3], blood 
vessels [4], macrophage [5], eye [6], bone [7], lung [8], and ovary [9]. 11βHSD1 regulates the access 
of glucocorticoid to steroid receptors by catalyzing the conversion of inactive cortisone into active 
cortisol.  11βHSD2  is  a  NAD
+-dependent  dehydrogenase  which  catalyzes  the  reverse  reaction  of 
11βHSD1 (converts the active cortisol into inactive cortisone). 11βHSD2 is mainly localized in the 
mineralocorticoid receptor (MR), and target tissues like kidney, colon, and salivary gland where it 
functions to protect the MR from excessive exposure to cortisol. 
11βHSD1  and  11βHSD2  share  a  high  similarity  with  other  members  of  the  short  chain 
dehydrogenase/reductase (SDR) family. Both the enzymes are functionally quite different and catalyze 
the interconversion of glucocorticoids (Figure 1). The SDR family enzymes shares a conserved α/β 
nucleotide-binding Rossman fold which consists of five parallel β-sheets flanked by three α-helices on 
the right and left side each. SDR reactions are catalyzed by a Tyr-(Xaa)3-Lys motif, often combined 
with  a  conserved  Ser  which  helps  to  orientate  the  substrates  in  a  suitable  position.  From  all  the 
reported 11βHSD1 crystal structures we observed that the co-crystal ligand showed a close vicinity to 
the co-factor as well as the catalytic amino acid Tyr183. The ligand orientation in the active site of 
11βHSD1 was well stabilized by the strong interaction with Ser170. 
Figure 1. Enzymes involved in the conversion of inactive cortisone to active cortisol. 
 
Elevated  levels  of  11βHSD1  develop  the  metabolic  syndrome-like  phenotypes  and  also  resist 
weight gain on a high-fat diet which is associated with increased energy expenditure and improved Int. J. Mol. Sci. 2012, 13  5140 
 
glucose  tolerance  as  well  as  insulin  sensitivity  [10].  There  are  several  factors  which  regulate  the 
11βHSD1 function such as hormones, transcriptional factors, co-factors, growth factor, tumor necrosis 
factor-β, and gonadal steroids [11]. Hence, 11βHSD1 inhibition could be a promising approach for the 
treatment of diabetes, cardiovascular, and metabolic syndromes [12–14]. The metabolic activation of 
cortisol is by one of the glucocorticoid hormones from a cortisone precursor and is exclusively carried 
out by 11βHSD1. The specific inhibition of 11βHSD1 emerges as a promising novel drug target in 
metabolic disease and other glucocorticoid-related syndromes due to the central role of cortisol in 
metabolic  syndromes  like  obesity,  insulin  resistance,  dyslipidemia,  and  arterial  hypertension. 
Unregulated overexpression of cortisol, manifested in Cushing’s disease is genetic evidence for the 
role  of  11βHSD1  in  diabetes  and  obesity.  Suppression  of  11βHSD1  function  may  retard  the 
development of antherosclerosis and hence it acts as a potential treatment for metabolic syndrome, 
diabetes,  and  cardiovascular  disease.  Therefore,  inhibitors  of  11βHSD1  are  very  attractive  to  the 
pharmaceutical industry and researchers. 
In recent years, several classes of 11βHSD1 inhibitors have been disclosed. In 2002, Barf et al. [15] 
reported 2-aminothiazole sulfonamides as the first selective 11βHSD1 inhibitors. Yang  et al. [16] 
described the important chemical features from a structure-based hypothesis, as well as highlighting 
that the hydrogen bond interaction between the ligand and Tyr183 or Ser170 plays a crucial role in the 
11βHSD1 inhibition. Ligand-based pharmacophore modeling is one of the productive tools to identify 
the important chemical features of the inhibitor as well as to improve its potency and pharmacokinetic 
properties. In this work, the known 11βHSD1 inhibitors were collected from the literatures to generate 
and validate the 3D pharmacophore models. The reported structure-based pharmacophore models have 
been compared with our ligand-based pharmacophore model to select the important chemical features 
responsible for inhibiting the 11βHSD1 function. A hypothesis was developed based on the reported 
inhibitors of 11βHSD1 and the best hypothesis was used to screen several databases  as an initial 
filtration in virtual screening. The screened molecules were subjected to a molecular docking study to 
find the suitable orientation and hydrogen bond interactions  between the lead compounds and the 
active residues such as Try183 and Ser170. Orbital energy values were calculated to find the reactivity 
of the lead compounds by applying density functional theory (DFT). 
2. Results and Discussion 
Pharmacophore modeling is a widely utilized method in the computer-aided drug design process. 
Within this framework two major domains are covered: virtual screening for a new lead which is 
nothing but  a ―scaffold hopping‖; and  systematization  of activity distribution  within the group of 
molecules, displaying a similar pharmacological profile that is recognized by the same target. The 3D 
pharmacophore modeling was used to identify the critical chemical features of 11βHSD1 inhibitors. 
The best hypothesis model was selected and validated based on its predictability in terms of activity 
and used to guide the rational design of 11βHSD1 inhibitors. Int. J. Mol. Sci. 2012, 13  5141 
 
2.1. Pharmacophore Generation 
The selection of chemical features plays an important role in determining the hypothesis quality.  
Yang  et  al.  in  2008  reported  a  quantitative  hypothesis  of  six  features  which  consists  of  
L-hydrogen bond acceptor (HBA), 1-ring aromatic (RA), and 4-hydrophobic (Hy) chemical features. 
Hence,  these  chemical  features  were  selected  based  on  the  reported  quantitative  ligand-based 
pharmacophore models. During the development of pharmacophore models generation, the training set 
molecules (Figure 2) were mapped to the chemical features in the hypothesis with their predetermined 
conformations  which  were  generated  using  the  Best  conformation  module.  The  pharmacophore 
generated ten alternative hypotheses based on the reported IC50 values of 11βHSD1 inhibitors. All 
hypotheses include chemical features such as HBA, RA, and hydrophobic aliphatic (Hy-Ali), hence 
these chemical features were assumed to be critical for the inhibition of 11βHSD1 function. Among 
ten hypotheses, one hypothesis was chosen as a best pharmacophore model based on its statistical 
parameters such as highest correlation coefficient, good cost difference, and lowest RMSD. 
Figure 2. Thirty chemically diverse compounds with their IC50 values in brackets used as 
training set in 3D-QSAR Discovery Studio/Pharmacophore generation. 
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2.1.1. Selection of the Best Hypothesis by Debnath Analysis 
The quality of the generated pharmacophore model is best described in terms of fixed cost, null cost, 
and total cost defined by Debnath [17]. The fixed cost stands for an ideal hypothesis that perfectly fits 
the estimated and experimental activity values with minimum deviation. The null cost represents the 
cost of a hypothesis with no features that estimates activity to be average [18]. The difference between 
the fixed and null cost should be greater or equal to 60 bits. The highest value indicates a greater 
chance of finding a useful hypothesis and also reflects the chance correlation. In this study, the cost 
difference  for  all  ten  hypotheses  was  higher  than  60  bits  which  represented  the  90%  statistical 
significance of the pharmacophore models. Hypo1 was believed to be statistically relevant and selected 
as a best hypothesis based on the following criteria, such as the highest cost difference (157.30), 
lowest error cost (117.67), the lowest RMS (1.21) divergence, and the best correlation coefficient 
(r:0.94) (Table 1). Perceptibly, all the above results demonstrated that Hypo1 was a reliable hypothesis 
with a good predictive power. 
Table  1.  Information of statistical significance values measured in bits for the top ten 
hypotheses as a result of automated 3D-QSAR pharmacophore generation. 
Hypo No.  Total Cost
  Cost Difference 
a  RMS  Correlation 
Features 
b 
Max. Fit 
HBA  Hy-Ali  RA 
Hypo1  133.91  157.30  1.21  0.94  1  1  2  11.81 
Hypo2  136.12  155.09  1.26  0.93  1  1  2  11.09 
Hypo3  136.85  154.36  1.26  0.93  1  1  2  12.51 
Hypo4  142.56  148.65  1.49  0.91  1  1  2  10.57 
Hypo5  153.2  138.01  1.69  0.88  1  1  2  11.09 
Hypo6  158.37  132.84  1.85  0.85  1  2  1  8.28 
Hypo7  161.76  129.45  1.86  0.85  1  1  2  11.01 
Hypo8  164.01  127.20  1.95  0.84  1  1  2  8.67 
Hypo9  164.08  127.13  1.79  0.87  1  2  1  13.13 
Hypo10  165.89  125.32  1.98  0.83  1  2  1  8.86 
a Cost difference between the null and the total cost; 
b Abbreviation used for features; HBA, Hydrogen Bond 
Acceptor; Hy-Ali, Hydrophobic Aliphatic; RA, Ring Aromatic. 
2.1.2. Score Hypothesis 
All the training set compounds were classified into three categories based on their IC50 values such 
as highly active, moderately active, and low active. Hypo1 was used to screen the training set to 
anticipate  as  well  as  to  evaluate  the  predicted  and  experimental  activity  value  of  the  compounds  
(Table 2). All the training set compounds showed an error value of less than ten which indicates only 
one order of magnitude of difference was observed in the discrepancy between the predicted and 
experimental activity. This variation may be due to the difference in the number of degrees of rotation 
of molecules which mismatched with Hypo1. Considering the above evaluations, Hypo1 was selected 
as a reliable best pharmacophore model to describe the structure activity relationship of 11βHSD1 
inhibitors. The most active compound 1 (IC50: 0.1 nM) showed a fitness score value of 9.37 when Int. J. Mol. Sci. 2012, 13  5143 
 
mapped to Hypo1, whereas the least active compound 30 (IC50: 53,000 nM) showed a fit value of 5.38 
(Figure 3). This result indicates that Hypo1 consists of a reasonable pharmacophoric characteristic of 
11βHSD1 inhibitors. Hence the small molecules which satisfy the chemical features of Hypo1 such as 
one  HBA,  one  Hy-Ali,  and  two  RA  chemical  features  with  the  specific  geometric  orientation  
(Figure 4) will be good inhibitors for 11βHSD1. 
Figure 3. Best pharmacophore model Hypo1 aligned to training set compound (a) Active 
molecule  compound  1  (IC50  0.1  nM);  (b)  Inactive  molecule  compound  18  
(IC50 53000 nM). Pharmacophore features are color coded (Hy-Ali, hydrophobic aliphatic, 
blue; RA, ring aromatic, brown and HBA, hydrogen bond acceptor, green). 
 
Figure 4. HypoGen pharmacophore model Hypo1 and its geometric constrains, where RA 
(ring aromatic), Hy-Ali (hydrophobic aliphatic) and HBA (hydrogen bond acceptor) are 
illustrated in brown, blue and green, respectively. 
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Table  2.  Actual  and  estimated  activity  of  the  training  set  molecules  based  on  the 
pharmacophore model Hypo1. 
Compound 
No. 
Fit 
Value 
a 
Exp.IC50 
nM 
Pred.IC50 
nM 
Error
  Exp. Scale 
b  Pred. Scale 
b 
1  9.39  0.1  0.61  6.1  +++  +++ 
2  8.49  0.88  4.9  5.5  +++  +++ 
3  9.5  1.1  0.48  −2.3  +++  +++ 
4  9.4  1.1  0.6  −1.8  +++  +++ 
5  8.54  1.4  4.3  3.1  +++  +++ 
6  8.71  1.7  2.9  1.7  +++  +++ 
7  9.45  2  0.53  −3.8  +++  +++ 
8  8.62  2.4  3.6  1.5  +++  +++ 
9  8.03  2.5  14  5.6  +++  ++ 
10  8.72  3.6  2.9  −1.3  +++  +++ 
11  8.52  3.8  4.5  1.2  +++  +++ 
12  8.17  4  10  2.5  +++  ++ 
13  8.71  4.6  3  −1.6  +++  +++ 
14  8.71  4.7  3  −1.6  +++  +++ 
15  8.55  5.5  4.3  −1.3  +++  +++ 
16  8.6  6.5  3.8  −1.7  +++  +++ 
17  8.2  10  9.5  −1.1  ++  +++ 
18  7.33  11  71  6.4  ++  ++ 
19  7.84  16  22  1.4  ++  ++ 
20  7.95  17  17  −1  ++  ++ 
21  7.87  35  20  −1.7  ++  ++ 
22  8.46  36  5.2  −6.9  ++  + 
23  7.7  79  30  −2.7  ++  ++ 
24  6.91  110  180  1.7  +  + 
25  5.84  500  2200  4.4  +  + 
26  5.61  1000  3700  3.7  +  + 
27  5.48  13,000  5000  −2.6  +  + 
28  5.49  20,000  4900  −4.1  +  + 
29  5.4  20,000  5900  −3.4  +  + 
30  5.4  53,000  6000  −8.8  +  + 
a  Fit  value  indicates  how  well  the  features  in  the  pharmacophore  overlap  the  chemical  features  in  the 
molecule. Fit = weight x [max (0, 1 − SSE)] where SSE = (D/T)
2, D = displacement of the feature from the 
center  of  the  location  constraints  and  T  =  the  radius  of  the  location  constraint  sphere  for  the  feature 
(tolerance); 
b Activity scale: IC50 < 10 nM = +++ (highly active); 10 nM ≤ IC50 < 100nM = ++ (moderately 
active); IC50 ≥ 100 nM = + (low active). 
2.2. Pharmacophore Validation 
2.2.1. Fischer’s Randomization Test 
Fischer’s  test  was  applied  to  evaluate  the  statistical  significance  of  Hypo1  based  on  statistical 
validation. In this method the experimental activity values of training set compounds were scrambled 
randomly and subsequently the scrambled datasets were used to generate the number of hypotheses Int. J. Mol. Sci. 2012, 13  5145 
 
depending on their significant levels. All the parameters were set as in the initial hypothesis generation. 
This validation was to check if there was any strong correlation between the structures and activity 
values. For this study, we selected the 98% confidence level; hence 49 random spreadsheets were 
produced by mixing up the experimental activity values present in the training set. By analyzing the 
resultant 49 hypotheses, Hypo1 was shown to be far superior to the 49 random pharmacophore models 
(Figure 5). This cross validation confirmed that there was a 98% chance of the pharmacophore model 
representing a true correlation in the training set activity data and thus gave us strong confidence in Hypo1. 
Figure 5. The difference in costs between HypoGen runs and the scrambled runs. The 98% 
confidence level was selected. 
 
2.2.2. Test Set Method 
A good pharmacophore model should predict the correct activity range of independent compounds 
present in the test set. The test set, containing 20 structurally different molecules from the training set, 
was used to validate the predictability of the Hypo1. All the test set compounds were prepared in the 
same  way  and  classified  into  three  categories  as  training  set  compounds  such  as  highly  active, 
moderately  active  and  low  active  molecules.  In  general,  a  compound  with  the  highest  fit  value 
corresponds to a compound which has a good activity value. In analyzing the error value of the test set, 
we found that all error values were less than two and the regression analysis of experimental and 
predicted inhibitory activity values (Table 3) gave a fairly good correlation coefficient of 0.93 which 
indicates  good  predictive  ability  of  Hypo1.  Therefore,  it  is  obvious  that  Hypo1  is  capable  of 
quantitatively distinguishing between highly, moderately, and low active compounds. Int. J. Mol. Sci. 2012, 13  5146 
 
Table 3. Experimental and predicted IC50 data values of 20 test set molecules against Hypo1. 
Compound 
No. 
Fit 
Value 
a 
Exp. 
IC50nM 
Pred. 
IC50nM 
Error 
Exp. 
Scale 
b 
Pred. 
Scale 
b 
1  7.273  2.90  2.94  +1.01  +++  +++ 
2  8.711  7.20  8.66  +1.20  +++  +++ 
3  5.202  11  17.54  +1.59  ++  ++ 
4  6.608  22  41.42  +1.88  ++  ++ 
5  6.549  74  80.70  +1.09  ++  ++ 
6  6.721  123  424.94  +3.45  +  + 
7  7.936  218  257.82  +1.18  +  + 
8  5.82  282  287.97  +1.02  +  + 
9  6.769  381  373.32  −1.02  +  + 
10  6.181  381  427.44  +1.12  +  + 
11  6.255  850  842  −1.01  +  + 
12  5.603  980  997.78  +1.02  +  + 
13  8.243  1730  1182.70  −1.46  +  + 
14  6.009  2050  2079.91  +1.01  +  + 
15  7.563  2130  2824.87  +1.33  +  + 
16  5.729  2250  1791.88  −1.26  +  + 
17  5.862  2350  1096.74  −2.14  +  + 
18  5.977  4670  3576  −1.31  +  + 
19  6.552  10000  1850.38  −5.40  +  + 
20  4.857  10000  21026  +2.10  +  + 
a  Fit  value  indicates  how  well  the  features  in  the  pharmacophore  overlap  the  chemical  features  in  the 
molecule. Fit = weight x [max (0, 1 − SSE)] where SSE = (D/T)
2, D = displacement of the feature from the 
center  of  the  location  constraints  and  T  =  the  radius  of  the  location  constraint  sphere  for  the  feature 
(tolerance); 
b Activity scale : IC50 < 10 nM = +++ (highly active); 10 nM ≤ IC50 < 100nM = ++ (moderately 
active); IC50 ≥ 100 nM = + (low active). 
2.2.3. Decoy Set 
Finally,  a  decoy  set  was  generated  to  evaluate  the  efficiency  of  Hypo1  using  a  Ligand 
Pharmacophore  Mapping  module  by  computing  GH  and  EF.  The  decoy  set  contains  13  active 
11βHSD1 inhibitors and 1287 inactive or the unknown activity compounds for 11βHSD1. The total 
number of compounds in the database (D) 1300, 12 compounds in the hit list (Ht), 75% active yields 
(%Y), 69.23% ratio of actives in the hit lists (%A), values of EF (7.5) and GH (0.73) are all a very 
good indication of the high efficiency of Hypo1 (Table 4). From the overall validations, we were 
assured that Hypo1 can predict most of the estimated and experimental activity of molecules in the 
same order of magnitude as well as it can discriminate the active inhibitors from inactive compounds 
as confirmed by the test and statistical parameters of the decoy sets, respectively. Int. J. Mol. Sci. 2012, 13  5147 
 
Table 4. Statistical parameters from screening of the decoy sets of molecules. 
No.  Parameter
  Values
 
1  Total number of molecules in database  1300 
2  Total number of actives in database (A)  13 
3  Total number of hit molecules from the database (Ht)  12 
4  Total number of active molecules in hit list (Ha)  9 
5  % yield of actives[(Ha/Ht) × 100]  75 
6  % Ratio of actives [(Ha/A) ×  100]  69.23 
7  Enrichment Factor (EF)  7.5 
8  False negatives [A − Ha]  4 
9  False Positives [Ht − Ha]  3 
10  Goodness of fit score (GH)  0.73 
Initially the best quantitative hypothesis, Hypo1, was compared with the reported structure based 
hypothesis  of  Yang  et  al.  The  refined  structure-based  pharmacophore  model  consists  of  
1-HBA, 1HBD, and 4-Hy chemical features and our best hypothesis  (Hypo1)  consists of 1-HBA,  
2-RA,  and  1-Hy  chemical  features.  The  difference  between  these  two  hypotheses  may  be  due  to 
molecular structure diversity. Hypo1 lacks the HBD chemical feature which was mentioned, in that it 
forms strong interactions between the ligand and its cofactor. The same group in 2008 developed a 
quantitative hypothesis which consisted of 4-Hy, 1-HBA, and 1-RA groups. Interestingly, all these 
three different types of hypotheses indicated that the HBA, Hy chemical features play a critical role in 
the inhibition of 11βHSD1. 
2.3. Pharmacophore Model Based Virtual Screening  
The best hypothesis, Hypo1, was used as a 3D query for retrieving potent compounds from the 
chemical databases such as NCI, Maybridge, and Chembridge. As a first screening, Hypo1 retrieved 
6,378, 20,021, and 13,470 compounds from NCI, Maybridge, and Chembridge, respectively. To sort 
out these molecules, a maximum fit value of 11 was applied which reduced the number of molecules to 
375 from NCI, 1192 from Maybridge and 440 from Chembridge. These hit molecules were further 
sorted by applying the Lipinski’s rule of five and ADMET to give them more drug-like properties. 
According to the rule of five, compounds are considered likely to be well absorbed when they possess 
LogP of less than five, molecular weight less than 500, number of HBD less than five, number of HBA 
less than ten, and number of rotatable bonds less than ten. The molecular flexibility of molecules and 
the total number of HBAs and HBDs are found to be important predictors for a compound to have a 
good oral bioavailability. The ADMET functionality was used to estimate the values of Brain Blood 
Barrier (BBB) penetration, solubility, Cytochrome P450 (CYP450) 2D6 inhibition, Hepatotoxicity, 
Human intestinal absorption (HIA), Plasma Protein Binding (PPB), and to access a broad range of 
toxicity measure of the ligands. Among all these criteria, we mainly focused on BBB (cut-off value 3), 
solubility  (cut-off  value  3),  and  HIA  (cut-off  value  0)  because  these  are  important  criteria  for  a 
compound to have a good oral bioavailability drug. Totally, 165 compounds (73 NCI, 65 Maybridge, 
and  27  Chembridge)  have  satisfied  all  the  physiological  properties  to  be  ideal  lead  molecules  
(Figure 6). Thus, these molecules were subsequently subjected into the molecular docking to reduce 
the false positive rate. Int. J. Mol. Sci. 2012, 13  5148 
 
Figure 6. Mapping of hit molecules by Hypo1 from chemical databases. (a) Maybridge;  
(b) Chembridge; (c) NCI. Pharmacophore features are color coded Hy-Ali, hydrophobic 
aliphatic, blue; RA, ring aromatic, brown and HBA, hydrogen bond acceptor, green. 
 
2.4. Molecular Docking 
Biomolecular interactions  and binding properties were analyzed for  the hit  molecules from  the 
virtual screening using GOLD molecular docking software. Three dimensional complex structure of 
11βHSD1 (PDB ID: 3FRJ) was taken from the PDB as a receptor. Initially the co-crystal was docked 
in the active site of 11βHSD1 to check whether the selected parameters are able to produce the most 
suitable  binding  orientation.  The  result  revealed  that  GOLD  can  perfectly  reproduces  the  similar 
orientation of the co-crystal. Then,  GOLD  was used to  refine the retrieved 165 hit molecules  by 
docking into the inhibitor binding site of the 11βHSD1 and the Gold fitness score was used to select 
the  docked  compounds.  The  well  docked  small  molecules  with  lowest  docked  energy  as  well  as 
average Gold fitness score were enumerated. The active molecules from the training set shows a Gold 
fitness value in the range of 61–70 but the moderately active molecules shows a value lesser than 60. 
Thus a Gold fitness score value of greater than 60 was considered as the cut off value to select the 
docked hit compounds from the virtual screening. The most stable docking models (47 compounds) 
were  selected  according  to  the  best-scored  conformation  by  the  Gold  fitness  score  function.  The 
molecules which show the greater value were manually checked for the hydrogen bond interactions 
with the critical amino acids like Tyr183, Ser170, and Ala172 of 11βHSD1. Among these molecules, 
17 molecules had shown good hydrogen bond interactions with Tyr183, Ser170 or Ala172 (Figure 7). 
The remaining 30 molecules had shown good interactions with the active residues Tyr183 but failed to 
show hydrogen bond interactions with Ser183 or Ala172. The compound 10978 was overlaid to check 
its docked pose orientation and the geometric constraints of Hypo1 (Figure 8). Finally, 17 compounds 
(Table 5) have satisfied all the above filtering methods and all the critical chemical features of Hypo1, 
docking score, and drug-like properties. Int. J. Mol. Sci. 2012, 13  5149 
 
Figure  7.  The  orientation  of  hit  molecules  in  the  active  site  of  11βHSD1.  
Green color—leads and hydrogen bonds in black are shown. 
 
Figure 8. (a) Compound 10978 fit with Hypo1 was overlaid in the active site of 11βHSD1 
crystal structure (PDB ID: 3REI) represented as ribbon; (b) overlay of compound 10978 
with docked pose and geometric constraint of Hypo1; (c) overlay of compound 10978 with 
docked pose and geometric constraint of Hypo1 without the hypothesis. Pharmacophore 
features are color coded (Hy-Ali, hydrophobic aliphatic, blue; RA, ring aromatic, brown 
and HBA, hydrogen bond acceptor, green). Green color molecules represent the Hypo1 fit 
molecule and violet color represents the dock pose. 
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Table 5. The Gold fitness scores for 17 leads from GOLD docking. 
Name  Structure  Gold Score  S(hb_ext)  S(vdw_ext) 
Compound 23516  S
N
N
O O O
O
O
O
O
 
62.61  2.05  44.05 
HTS 05706 
S
O
S
N
NH O
O
OH
O
 
64.01  0.61  46.11 
NCI0022030 
O
NH O
O
Cl
O
O
O
 
64.11  8.45  40.49 
NCI0025130 
O
S
O
O
N
O
O
N
O  
64.75  4.52  43.81 
KM 10378  S
O
N N
N N
OH
NH
S O
 
65.43  1.45  46.56 
SPB 02668 
OH
N
S N
N
N
N N
O
N
OH 
65.93  7.07  42.82 
RJC 03502 
N
O
NH
N
OH NH
N
N
O
 
66.29  1.08  47.45 
JFD 03179  O
N
O
O
NH
N
H
OH
 
66.84  1.42  47.62 
SCR 00436 
O H
O
N
N
S
NH
O
O  
67.04  0.15  48.68 Int. J. Mol. Sci. 2012, 13  5151 
 
Table 5. Cont. 
Name  Structure  Gold Score  S(hb_ext)  S(vdw_ext) 
SCR 00883  S
O
O
O
O
NH
N
S
S O
 
67.87  3.32  46.94 
Compound 10978 
S
N
N
N
O O
NH
O
O  
68.04  1.75  48.25 
HTS 07455 
NH
S
NH
S N
N N
O
NH
 
72.24  2.23  50.94 
HTS 08985 
NH
S
NH
S N
N N
O
NH
 
75.27  3.00  52.59 
NCI0050873 
O
OH
O O
O
O
O
O  
75.46  6.03  50.53 
KM 06091 
NH
NH
O
S
N
S
O
NH
 
75.56  4.00  52.07 
NCI0031862 
O
S N
O O
O
S N
O
O  
76.17  2.28  53.78 
SPB 07954 
NH
S
NH
S N
N N
O
O
NH
 
83.04  0.62  59.95 
2.5. Density Functional Theory 
The DFT has been applied to find the orbital energy values from which we can predict how well the 
group can donate or accept the electrons. Recently, many research articles reported the donating and 
accepting  ability  of  the  small  molecules  by  calculating  the  highest  occupied  molecular  orbital 
(HOMO) and lowest unoccupied molecular orbital (LUMO) values [19]. The most active 3 training set 
molecule classified based on their IC50 value such as Compound 9 (2.5 nM), Compound 12 (4 nM), 
Compound 17 (10 nM) along with 17 database hit compounds were taken into account of HOMO, 
LUMO calculation. The calculated HOMO, LUMO values of hit compounds were compared with the 
most active training set compounds to analyze their electronic properties such as electron donating and 
accepting  toward 11βHSD1. The frontier orbital,  HOMO, is  an important parameter of molecular 
electron structure. The higher HOMO value implies that the molecule has good electron donating 
ability; on the other hand, a lower value implies weak electron donating ability. The calculated HOMO, 
LUMO values have been summarized in Table 6. Int. J. Mol. Sci. 2012, 13  5152 
 
Table 6. Comparison of highest and lowest molecular orbital values for hit leads and active 
inhibitors of 11βHSD1. 
Name  Structure  HOMO
  LUMO
  ΔE 
a 
KM 06091 
NH
NH
O
S
N
S
O
NH
 
−8.31  −0.93  7.37 
HTS 08985 
NH
S
NH
S N
N N
O
NH
 
−8.44  −0.92  7.52 
Compound 10978 
S
N
N
N
O O
NH
O
O  
−8.47  −0.78  7.69 
HTS 07455 
NH
S
NH
S N
N N
O
NH
 
−8.48  −0.63  7.84 
SPB 07954 
NH
S
NH
S N
N N
O
O
NH
 
−8.51  −0.79  7.71 
Training9  Cl
Cl
S
O O O
N
N
 
−8.56  −1.20  7.35 
NCI0050873 
O
OH
O O
O
O
O
O
 
−8.73  −0.07  8.65 
Training12 
N N S
O
O
N
F
F F  
−8.74  −0.76  7.97 
Training17 
N N S
O
O
N
F
F F  
−8.89  −0.73  8.16 
HTS 05706 
S
O
S
N
NH O
O
OH
O
 
−8.93  −1.72  7.21 
KM10378 
S
O
N N
N N
OH
NH
S O
 
−8.95  −1.72  7.21 Int. J. Mol. Sci. 2012, 13  5153 
 
Table 6. Cont. 
SCR 00883  S
O
O
O
O
NH
N
S
S O
 
−9  −1.18  7.82 
SPB02668 
OH
N
S N
N
N
N N
O
N
OH 
−9.04  −1.86  7.18 
JFD03179  O
N
O
O
NH
N
H
OH
 
−9.07  −0.87  8.20 
NCI22030 
O
NH O
O
Cl
O
O
O
 
−9.11  −0.16  8.71 
NCI0025130 
O
S
O
O
N
O
O
N
O  
−9.32  −0.61  8.71 
NCI0031862 
O
S N
O O
O
S N
O
O  
−9.84  −1.11  8.73 
RJC03502 
N
O
NH
N
OH NH
N
N
O
 
−9.96  −1.44  8.52 
SCR00436 
O H
O
N
N
S
NH
O
O  
−9.56  −1.81  8.46 
a Energy difference between HOMO and LUMO orbital. 
In comparison with training set compounds 4, compounds from Maybridge (KM06091, HTS08985, 
HTS07455, SPB07954), and one compound from Chembridge (Compound 10978) have shown very 
high HOMO values. This demonstrates that the hit compounds have more electron donating ability 
than most active training set compounds. Moreover, HOMO-LUMO energy gap of training set and hit 
compounds were  calculated  to  check the  chemical  activity of the molecules suitable to  donate or 
accept electrons towards 11βHSD1. Further, the lowering of the energy gap demonstrates the eventual 
charge transfer interaction that takes place within the molecule [19]. In the present study, the five hit 
compounds  showed  lower  energy  gap  values  when  compared  with  the  most  active  training  set 
compounds. The atomic orbital compositions of the frontier molecular orbital for some  of the  hit 
compounds such as HTS08985 and Compound 10978 were sketched and shown in Figure 9. In the 
case of HTS08985, the highest molecular orbitals were located mainly for thiomethane and lowest for Int. J. Mol. Sci. 2012, 13  5154 
 
methylsulfonyltriazole. Hence the electronic transition from thiomethane to methylsulfonyltriazole and 
this result was confirmed by the molecular interaction of the compound in the protein active  site 
(Figure  7).  Compound  10978  has  also  shown  similar  results  which  was  also  confirmed  by  the 
molecular interaction. Based on the above results, the database hit compounds are more superior to 
most active compounds and could be used to design new classes of 11βHSD1 inhibitors. 
Figure 9. Highest and lowest molecular orbital plots for two lead compounds identified 
from the databases. 
 
3. Experimental Section 
3.1. Pharmacophore Modeling 
Pharmacophore modeling is one of the most potent and rapid method to discover the novel scaffolds 
from databases. Pharmacophore can be produced by two methods: based on the active site of protein 
and  also  the  properties  of  the  ligands.  The  ligand  based  pharmacophore  exists  in  two  different 
approaches: (i) based on common features of the molecules; and (ii) using the activity values and the 
structure  of  the  compounds.  In  this  study  we  employed  the  activity  based  pharmacophore  model 
generation method. 
Software: A pharmacophore was generated using HypoGen module in Accelrys Discovery Studio 
v2.5  (DS,  Accelrys,  San  Diego,  CA,  USA,  2011).  The  two-  and  three-dimensional  structures  of 
compounds were constructed using Chemsketch v11.02 and DS, respectively. 
3.1.1. Training and Test Set Preparation 
To construct training and test sets, totally we selected 50 structurally diverse compounds with the 
reported inhibitory activity values from literatures [20–26]. The constructed pharmacophore model can 
be as good as the information of input data. Hence, to achieve a best hypothesis, the training set must-
obey the rules in a 3D quantitative structure-activity relationship generation. The training set must 
consist of widely populated (at least 16 compounds) as well as it should have good structural diverse 
representatives  covering  an  activity  range  of  at  least  4  orders  of  magnitude.  The  most  active Int. J. Mol. Sci. 2012, 13  5155 
 
compounds should inevitably be included in the training set and all biologically relevant data should 
be  obtained  by  homogeneous  procedures  and  expressed  as  IC50  (i.e.,  concentration  of  compound 
required  to  inhibit  50%  of  11βHSD1).  All  the  structures  were  minimized  using  smart  minimizer 
algorithm which performs 1000 steps of steepest decent with a root mean square [1] gradient of 0.1, 
followed by conjugated gradient minimization. Among 50 molecules, 30 compounds were selected as 
training set and the remaining 20 compounds were taken as test set. The training set was selected based 
on the structural diversity and wide coverage of the activity values which spans across a wide range 
from 0.10 nM to 53,000 nM. In this modeling study, based on the activity values (IC50) the compounds 
are divided into three categories: compounds which have the activity values of <10 nM were classified 
as highly active (+++), those with activities between ≥10 nM and ≤100 nM were defined as moderately 
active and the compounds that have the activity values greater than 100 nM was classified as low 
active molecules. The significant aspect of this assortment to ensure that each active provide a clue to 
generate the hypothesis thus it can be able to bring out as much as vital information possible for 
predicting biological activity. 
3.1.2. Pharmacophore Generation 
DS provides two types of conformational analyses such as Fast and Best. Molecules might adjust 
their conformations when binding to a receptor hence the conformers was generated for each molecule 
to increase the flexibility during the generation of the pharmacophore. Conformational models of the 
training and test set compounds were generated using a Monte Carlo-like algorithm together with 
poling [27,28]. Instead of using lowest energy conformation of each compound, multiple acceptable 
conformations were generated for each compound specifying the maximum number of 255 conformers 
with a constraint of 20 kcal/mol energy and all other default parameters were used. 
For  the  pharmacophore  studies,  the  following  chemical  features  were  selected  using  Feature 
mapping, to get the essential information for hypothesis generation process: HBA, HBD, RA, Hy-Ali, 
positive ionization (PI), negative ionization (NI), and hydrophobic aromatic (Hy-Ar). The uncertainty 
factor for each compound represents the ratio of uncertainty in activity value based on the expected 
statistical straggling of biological data collection. The 30 training set molecules which are associated 
with  their  conformations  are  submitted  to  3D  QSAR  Pharmacophore  Generation.  It  produces  the 
hypothesis by undergoes three phases: constructive, subtractive, and optimization phases. The initial 
stage of the hypothesis generation is constructive phase which considers all possible pharmacophore 
configurations of the most active compounds to entail pharmacophore demands. Second phase is a 
subtractive phase, all possible pharmacophore configurations of the remain or discarded depending on 
the  number  of  least  active  training  set  members  that  share  a  pharmacophore  pattern.  Finally,  the 
optimization phase, candidate model within the pharmacophore space of a particular target through 
fine perturbation to pharmacophore hypotheses is evaluated. The hypothesis generation process stops 
when no better score of the hypothesis can be accomplished and the output parameters also determine 
the hypothesis quality. The regression parameter in pharmacophore generation module estimates the 
activity  of  each  training  set  which  computed  by  the  regression  analysis  using  the  relationship  of 
geometric fit value versus the negative logarithm of activity. The geometric fit value was calculated 
based on the fit function checking whether the feature is mapped or not and also assures whether it Int. J. Mol. Sci. 2012, 13  5156 
 
contains a distance term, which measures the distance that separates the feature on the molecule from 
the centroid of the hypothesis feature. Finally, the top 10 scoring hypotheses were exported which 
composed of above mentioned pharmacophore features. The best model was selected based on the 
statistical parameters like cost values which determine the significance of the model. The best model 
was further affirmed by various validations methods like Fischer’s randomization method, test and 
decoy sets. 
3.2. Methods to Select the Best Pharmacophore Model and to Validate the Hypothesis 
Among  the  10  hypothesis,  the  selected  best  hypothesis  should  be  able  to  identify  the  active 
compounds from external molecules (other than training set) and also to predict the activity of the 
molecules accurately. Therefore Debnath’s analysis was used to select the best hypothesis, Fisher’s 
randomization test method, test and decoy sets  were used to confirm the predictive ability of the  
best hypothesis. 
3.2.1. Debnath’s Analysis 
The success of any hypothesis is determine by two important theoretical cost calculations like fixed 
and null cost.  Fixed cost also known as ideal  cost that determines the simplest model which can 
perfectly fits all the data. Null cost also termed as no correlation cost, representing the highest cost of a 
pharmacophore with no features and estimates activity to the average of the activity data present in the 
training set. A significant pharmacophore model might obtain when the difference between the null 
and the fixed cost value is large. If the value between the 40–60% and greater than 60% bits represents 
that  the  pharmacophore  has  75–90%  and  greater  than  90%  probability  of  correlating  the  data, 
respectively. Other two parameters also play a major role to determine the quality of the hypothesis, 
such as configuration cost and error cost. The configuration cost also known as entropy cost based on 
the complexity of the pharmacophore hypothesis space and should have a value less than 17. The error 
cost is purely depends on RMSD between the predicted and experimental activities of training set 
compounds.  The  RMSD  represents  the  quality  of  correlation  between  predicted  and  experimental 
values. The best pharmacophore should have highest cost difference, eminent correlation coefficient 
and lowest RMSD. 
3.2.2. Fischer’s Randomization Test 
The predicted power of hypothesis  is  determine by evaluating  the statistical  significance using 
cross-validation procedure derived from Fischer’s randomization method. In this method the training 
set molecules were modified by scrambling the activity values for all the compounds. These stochastic 
spreadsheets yield a number of hypotheses without any statistical significance. To achieve the 98% 
statistical significance level, 49 random spreadsheets were generated. For 49 random spreadsheets, 
randomization will give 49 different hypotheses and its corresponding values like total cost, null cost, 
RMSD, correlation coefficient etc. When comparing these values with the best hypothesis, it should 
have a highest cost difference, lowest total cost, good correlation coefficient and lowest RMSD. This 
will further support the statistical significance of the best hypothesis. Int. J. Mol. Sci. 2012, 13  5157 
 
3.2.3. Test Set 
The best pharmacophore model which was selected based on Debnath’s has chosen to estimate the 
activity  of  the  test  set.  Test  set  contains  wide  range  of  activity  values  and  structurally  diverse 
compounds from the training set molecules and classified as highly active, moderately active and low 
active compounds based on its activity values. It was used to determine whether the selected best 
pharmacophore  model  has  the  capability  to  estimate  the  accurate  activity  value  for  the  external 
molecules other than training set. 
3.2.4. Decoy Set 
The enrichment factor for best pharmacophore model is calculated to prove the specificity and 
selectivity of model. A decoy set consists of 1300 molecules which includes 13 active molecules of 
11βHSD1 inhibitors. Decoy set was used to check how well the selected best hypothesis was able to 
discriminate the active 11βHSD1 inhibitor compounds from other molecules, based on parameters 
such as total number of compounds in the hit list (Ht), number of active percent of yields (%Y), 
percent ratio of actives in the hit list (%A), enrichment factor (EF) and goodness of fit (GH) was 
calculated using the Ligand pharmacophore mapping protocol. Equations (1) and (2) were used to 
calculate the EF and GH: 
EF = [(Ha × D)/(Ht × A)]  (1)  
GH = [(Ha/4HtA) (3A + Ht) ×  (1 − ((Ht – Ha)/(D − A))]  (2)  
where ―Ha‖ is the total number of actives molecules in the hit list, ―D‖ is total number of molecules in 
the decoy set and ―A‖ is the total number of actives in the decoy set. 
3.3. Virtual Screening 
Virtual screening of databases can be used to validate the quality of selected pharmacophore model 
which was generated based on the known inhibitory activity value of compounds as well as to pick the 
novel and potent molecule which satisfy all critical chemical features of the hypothesis for further drug 
development. Here, the Hypo1 comprises of four chemical features was used as 3D query to search a 
chemical databases like NCI [29] (~200,000 compounds), Maybridge [30] (~60,000 compounds), and 
Chembridge  [31]  (~50,000  compounds)  databases.  For  searching  databases,  Fast  Flexible  search 
algorithm  was  used to  retrieve the new scaffolds for 11βHSD1 inhibitors.  The drug-like property 
calculation was performed by applying Lipinski’s rule of five [32] and ADMET. Lipinski’s rule of five 
is a simple model to forecast the absorption and intestinal permeability of a compound. According to 
the rule of five, compounds are considered likely to be well absorbed when they possess LogP less 
than 5, molecular weight less than 500, number of hydrogen bond donors less than 5, number of 
hydrogen bond acceptors less than 10 and number of rotatable bonds less than 10. Mainly blood brain 
barrier (BBB), solubility and absorption criteria’s were focused on ADME, if the molecules have the 
level of 3 and 0 for solubility and absorption, respectively, these values represents that the molecules 
have good solubility and absorption. The drug should not cross the BBB, hence the level ―3‖ was 
selected means low penetration of BBB. Int. J. Mol. Sci. 2012, 13  5158 
 
3.4. Molecular Docking 
Molecular docking method can be classified into two parts: search strategy and scoring function. 
The conformational selection of compounds plays a high impact for the feasibility for the binding 
mode. GOLD 4.1 [33] (the Cambridge Crystallographic Data Centre, Cambridge, UK, 2009) performs 
docking of flexible ligands into protein with partial flexibility in the neighborhood of the active site 
based on a genetic algorithm [34]. This method allows a partial flexibility and full flexibility  for 
protein and ligand, respectively. Ten poses for each ligand were generated and ranked by GOLD 
fitness score. Three dimensional crystal structure model of 11βHSD1-piperidyl benzamide complex 
[PDB  ID: 3FRJ] was  selected from  Protein  Data Bank [35] (PDB, www.rcsb.org) to  perform  the 
docking experiments. The interaction sphere is center in the active site and delimited by an 8 Å radius 
was chosen by XYZ coordinates of the co-crystal in 11βHSD1. For each of the 100 independent GA 
runs, a maximum number of 100,000 GA operations were performed on a set of five groups with a 
population size of 100 individuals. Default cut off values of 2.5 Å for hydrogen bonds and 4.0 Å for 
the van der Waals distance were applied. The RMSD values for the docking calculation are based on 
the RMSD matrix of the ranked solutions. The hit molecules which had been screened from the virtual 
screening and 4 active and 1 moderately active compounds from the training set were docked and 
evaluated using the scoring function Gold fitness score and rank binding affinities. The novel scaffolds 
for 11βHSD1 were selected based on the Gold score as well the appropriate interactions with the 
critical residues. 
3.5. Density Functional Theory  
The  structural-activity  relationship  has  been  used  to  study,  the  better  understanding  of  the 
interactions  between  the  protein  and  ligand,  to  determine  the  electronic  properties  using  quantum 
chemistry  calculation  by  density  functional  theory.  Herein,  we  have  utilized  the  Gaussian03W 
molecular package [36], invoking gradient geometry optimization [37]. Geometries of the models have 
been first optimized with full relaxation on the potential energy surfaces at the HF/6-31G(d,p) level 
and the resultant geometries have been used as inputs for further calculations at the DFT (B3LYP) 
level to calculate the HOMO and LUMO for most active training set compound along with some of 
identified database hit compounds. The selection of database hit compounds based on their binding 
mode, molecular interaction at protein active site was only taken. Through we have calculated the 
electronic  properties  for  the  11βHSD1  inhibitors  as  well  as  leads.  HOMO  and  LUMO  are  very 
important parameters for quantum chemistry. We can determine the way the molecule interacts with 
other species; hence, they are called the frontier orbital’s. HOMO, which can be thought the outermost 
orbital containing electrons, tends to give these electrons such as an electron donor. On the other hand; 
LUMO can be thought the innermost orbital containing free places to accept electrons [38]. Owing to 
the interaction between HOMO and LUMO orbital of a structure, transition state transition of π-π* 
type is observed with regard to the molecular orbital theory [39]. Therefore, while the energy of the 
HOMO is directly related to the ionization potential, LUMO energy is directly related to the electron 
affinity. Energy difference between HOMO and LUMO orbital is called as energy gap (ΔE) that is an 
important stability for structures [40]. In our study, we compared the different structural features of Int. J. Mol. Sci. 2012, 13  5159 
 
hits compounds with the most active training set compound as well as to identify the better inhibitory 
activity toward 11βHSD1. 
4. Conclusions 
11βHSD1  is  a  therapeutic  target  for  type  2  diabetes  that  stimulates  the  interest  of  many 
pharmaceutical  companies  and  researchers.  11βHSD1  will  be  of  therapeutic  benefit  by  lowering 
glucose output and increasing the insulin sensitivity. From the results of this study we suggest that 
Hypo1 has the capability of predicting the activities over a wide variety of scaffolds and showed 
distinct chemical features that may be responsible for activity of inhibitors.  Hypo1 was generated 
based on 30 compounds in the training set consisting of 1-HBA, 1-Hy-Ali, 2-RA and indicates that 
these are the critical features of 11βHSD1 inhibitors. Fischer’s randomization method indicated that 
the Hypo1 did not come by chance. Test set validation confirmed that the Hypo1 is able to accurately 
differentiate the active from the inactive compounds, as well as a high correlation coefficient of 0.93 
and decoy set methods showed a high GH (0.73) as well as EF (7.5), indicating its quality. Thus, 
Hypo1 was used as a 3D query in the virtual screening process to screen large databases like NCI, 
Maybridge,  and  Chembridge  and  sorted  165  molecules  based  on  the  maximum  fit  value  of  (11), 
Lipinski’s Rule of Five and ADMET. These molecules were subjected to docking studies to find the 
suitable  orientation  of  compounds  in  the  active  site  of  11βHSD1.  Docking  results  revealed  that  
47 compounds showed a high Gold Score of greater than 60, 17 out of 47 molecules showed an 
hydrogen bond interaction with Tyr183, Ser170 or Ala172. These 17 hit molecules as well as the few 
active compounds of 11βHSD1 were used to compute the DFT to calculate the electronic properties of 
the hit compounds. By comparing the values of HOMO, LUMO and the energy gap between the 
HOMO and LUMO revealed that five hit compounds had good electronic properties when compared 
with the active 11βHSD1 inhibitors. Thus these five hit compounds could be useful to design the 
inhibitors  of  11βHSD1  with  greater  selectivity.  Hypo1  therefore  will  help  in  the  identification  or 
design of potent 11βHSD1 inhibitors for further biological evaluation and optimization. 
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